Your browser doesn't support javascript.
loading
Farnesyltransferase inhibitors versus Ras inhibitors.
Gibbs, J B; Graham, S L; Hartman, G D; Koblan, K S; Kohl, N E; Omer, C A; Oliff, A.
Afiliación
  • Gibbs JB; Merck Research Laboratories, West Point, PA 19486, USA. jay_gibbs@merck.com
Curr Opin Chem Biol ; 1(2): 197-203, 1997 Aug.
Article en En | MEDLINE | ID: mdl-9667853
ABSTRACT
Over the past few years, the idea that farnesyl-protein transferase (FPTase) inhibitors might be effective antiproliferative/antitumor agents has been realized in studies of cultured cells and in rodent models of cancer. Most of the studies with FPTase inhibitors have focused on inhibiting the growth of ras-transformed cells in vitro or the growth of ras-dependent tumors in mice. More recently, it has been recognized that the antiproliferative effect of FPTase inhibitors may extend beyond ras-driven tumors. It now seems likely that the ability of FPTase inhibitors to reverse the malignant phenotype results, at least in part, from inhibiting the farnesylation of proteins other than Ras.
Asunto(s)
Buscar en Google
Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Genes ras / Transferasas Alquil y Aril / Inhibidores Enzimáticos / Antineoplásicos Límite: Humans Idioma: En Revista: Curr Opin Chem Biol Asunto de la revista: BIOQUIMICA Año: 1997 Tipo del documento: Article País de afiliación: Estados Unidos
Buscar en Google
Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Genes ras / Transferasas Alquil y Aril / Inhibidores Enzimáticos / Antineoplásicos Límite: Humans Idioma: En Revista: Curr Opin Chem Biol Asunto de la revista: BIOQUIMICA Año: 1997 Tipo del documento: Article País de afiliación: Estados Unidos